132 related articles for article (PubMed ID: 7512845)
1. Differential effect of 4-hydroperoxycyclophosphamide and antimyeloid monoclonal antibodies on T and natural killer cells during bone marrow purging.
Zhong RK; Donnenberg AD; Rubin J; Ball ED
Blood; 1994 Apr; 83(8):2345-51. PubMed ID: 7512845
[TBL] [Abstract][Full Text] [Related]
2. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
[TBL] [Abstract][Full Text] [Related]
3. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
Ericson SG; Colby E; Welch L; Ball ED
Bone Marrow Transplant; 1992 Feb; 9(2):129-37. PubMed ID: 1373982
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies.
Gulati SC; Shimazaki C; Lemoli RM; Atzpodien J; Clarkson BD
Eur J Haematol Suppl; 1989; 51():164-72. PubMed ID: 2627987
[TBL] [Abstract][Full Text] [Related]
5. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
[TBL] [Abstract][Full Text] [Related]
6. A combination of anti-CD15 monoclonal antibody PM-81 and 4-hydroperoxycyclophosphamide augments tumor cytotoxicity while sparing normal progenitor cells.
Rubin J; Malley V; Ball ED
J Hematother; 1994; 3(2):121-7. PubMed ID: 7922015
[TBL] [Abstract][Full Text] [Related]
7. Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells.
Uckun FM; Gajl-Peczalska K; Meyers DE; Ramsay NC; Kersey JH; Colvin M; Vallera DA
Blood; 1987 Jan; 69(1):361-6. PubMed ID: 3098325
[TBL] [Abstract][Full Text] [Related]
8. Generation of human natural killer cells from pharmacologically purged bone marrow.
Silva MR; Ascensao JL
Br J Haematol; 1995 Jan; 89(1):34-40. PubMed ID: 7833274
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of lymphokine-activated killer cells generated from bone marrow mononuclear cells for the purging of residual tumor cells in peripheral blood stem cell graft.
Komatsu F; Kajiwara M
Jpn J Cancer Res; 1996 Feb; 87(2):161-9. PubMed ID: 8609065
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation.
Long GS; Hiserodt JC; Harnaha JB; Cramer DV
Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797
[TBL] [Abstract][Full Text] [Related]
11. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
[TBL] [Abstract][Full Text] [Related]
12. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
13. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging.
Uckun FM; Kersey JH; Vallera DA; Ledbetter JA; Weisdorf D; Myers DE; Haake R; Ramsay NK
Blood; 1990 Nov; 76(9):1723-33. PubMed ID: 2224122
[TBL] [Abstract][Full Text] [Related]
14. Reactivity profiles of leukemic myeloblasts with monoclonal antibodies directed to sialosyl-Le(x) and other lacto-series type 2 chain antigens:absence of reactivity with normal hematopoietic progenitor cells.
Muroi K; Suda T; Nojiri H; Ema H; Amemiya Y; Miura Y; Nakauchi H; Singhal A; Hakomori S
Blood; 1992 Feb; 79(3):713-9. PubMed ID: 1370643
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
Casorati G; Locatelli F; Pagani S; Garavaglia C; Montini E; Lisini D; Turin I; Rossi F; Dellabona P; Maccario R; Montagna D
Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
Stiff PJ; Schulz WC; Bishop M; Marks L
Blood; 1991 Jan; 77(2):355-62. PubMed ID: 1985700
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
[TBL] [Abstract][Full Text] [Related]
18. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
19. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.
De Fabritiis P; Bregni M; Lipton J; Greenberger J; Nadler L; Rothstein L; Korbling M; Ritz J; Bast RC
Blood; 1985 May; 65(5):1064-70. PubMed ID: 3995166
[TBL] [Abstract][Full Text] [Related]
20. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
